



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Cernerud et al.  
Serial No. : 10/622,055  
Filed : July 17, 2003  
Title : NEW COMPOUNDS

Art Unit : 1614  
Examiner : Unknown  
Conf. No. : 2277

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.

References AQ, AT, AII, AWW, and ABBB are non-English language documents. Each of the aforementioned references include an English language abstract. Applicants submit that these English language abstracts fulfill the requirement for providing a concise explanation of relevance for non-English language references AQ, AT, AII, AWW, and ABBB (see MPEP § 609).

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

June 27, 2006

Date of Deposit

Signature

Jennifer Robins

Typed or Printed Name of Person Signing Certificate

07/05/2006 RHEBRAHT 00000114 10622055

01 FC:1806

180.00 OP


Applicant : Cernerud et al.  
Serial No. : 10/622,055  
Filed : July 17, 2003  
Page : 2 of 2

Attorney's Docket No.: 13425-122001 / BV-1031-US  
Reg

This statement is being filed after a first Office action on the merits, but before receipt of a final Office action or a Notice of Allowance. A check for \$180 in payment of the late submission fee of §1.17(p) is enclosed. Please apply any other charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No.: 13425-122001.

Respectfully submitted,

Date: June 27, 2006

  
\_\_\_\_\_  
John T. Kendall, Ph.D.  
Reg. No. 50,680

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

Substitute Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
13425-122001Application No.  
10/622,055**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.99(b))

Applicant  
Cernerud et al.Filing Date  
July 17, 2003Group Art Unit  
1614**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,134,149	07/28/92	Carr, et al.			
	AB	5,538,974	07/23/96	Ogawa et al.			
	AC	6,143,792	11/07/00	Cattelin			
	AD	6,358,977	03/19/02	Carlsson			

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AE	EP 0522226A1	12/20/91	EPO				
	AF	EP 0695545A1	06/14/95	EPO				
	AG	WO 00/12090	03/09/00	WIPO				
	AH	WO 01/89498 A2	11/29/01	WIPO				

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AI	Abbot, F.V., et al., "Activation of 5-HT <sub>2A</sub> Receptors Potentiates Pain Produced by Inflammatory Mediators", <i>Neuropharmacology</i> , vol. 35(1), pp. 99-110, 1996.
	AJ	Apelqvist, J., et al., "Ketanserin in the treatment of diabetic foot ulcer with severe peripheral vascular disease", <i>International Angiology</i> , vol. 9, pp. 120-124, 1990.
	AK	Bush, L.R., et al., "The Role of the Endothelium in Arterial Thrombosis and the Influence of Antithrombotic Therapy", <i>Drug Development Research</i> , vol. 7, pp. 319-340, 1986.
	AL	Cohen, M.L., "Canine, but not rat bladder contracts to serotonin via activation of 5HT <sub>2</sub> receptors", <i>The Journal of Urology</i> , vol. 143, pp. 1037-1040, 1990.
	AM	Costagliola, C., et al., "Effect of topical ketanserin administration on intraocular pressure", <i>British Journal of Ophthalmology</i> , vol. 77, pp. 344-348, 1993.
	AN	Danton, G., et al., "Endothelium-targeted pharmacotherapeutics for the treatment of stroke", <i>Current Opinion in Investigational Drugs</i> , vol. 3(6), pp. 896-904, 2002.
	AO	Dietrich, W.D., et al., "Effect of the serotonin antagonist ketanserin on the hemodynamic and morphological consequences of thrombotic infarction", <i>Journal of Cerebral Blood Flow and Metabolism</i> , vol. 9, pp. 812-820, 1989.
	AP	Dursun, S.M., et al., "An exploratory approach to the serotonergic hypothesis of depression: bridging the synaptic gap", <i>Medical Hypotheses</i> , vol. 56(2), pp. 235-243, 2001.
	AQ	Furukawa, K., et al., "Therapeutic effects of sarpogrelate hydrochloride (MCI-9042) on chronic arterial occlusive diseases: a double-blind comparison with ticlopidine hydrochloride", <i>J. Clin. Ther. Med.</i> 1991, 7, 1747-1770.
	AR	Gelders, Y.G., "Thymosthenic agents, a novel approach in the treatment of schizophrenia", <i>British Journal of Psychiatry</i> , vol. 155(suppl.), pp. 33-36, 1989.

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13425-122001	Application No. 10/622,055
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Cernerud et al.	
		Filing Date July 17, 2003	Group Art Unit 1614

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AS	Hara, N., et al., "Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models", <i>Thrombosis and Haemostasis</i> , vol. 66(4), pp. 484-488, 1991.
	AT	Hemmeter, U., et al., "Schlafstorungen bei chronischen schmerzen und generalisierter tendomyopathie", <i>Schweiz Med Wochenschr</i> , vol. 125, pp. 2391-2397, 1995. (Abstract Only)
	AU	Hotta, N., et al., "Effects of the 5-HT <sub>2A</sub> receptor antagonist sarpogrelate in diabetic patients with complications", <i>Clin Drug Invest</i> , vol. 18(3), pp. 199-207, 1999.
	AV	Ichiyanagi, N., et al., "Changed responsiveness of the detrusor in rabbits with alloxan induced hyperglycemia: Possible role of 5-hydroxytryptamine for diabetic bladder dysfunction", <i>The Journal of Urology</i> , vol. 168, pp. 303-307, 2002.
	AW	Ishimura, E., et al., "Therapeutic effect of sarpogrelate, a new 5-hydroxytryptamine receptor 2A antagonist, on diabetic nephropathy and neuropathy", <i>Nephron</i> , vol. 76, pp. 227-229, 1997.
	AX	Jackson, J., et al., "Enhancement of [m-methoxy 3H]MDL100907 binding to 5HT <sub>2A</sub> receptors in cerebral cortex and brain stem of streptozotocin induced diabetic rats", <i>Molecular and Cellular Biochemistry</i> , vol. 199, pp. 81-85, 1999.
	AY	Kaplan, S.A., et al., "Urodynamic findings in patients with diabetic cystopathy", <i>The Journal of Urology</i> , vol. 153, pp. 342-344, 1995.
	AZ	Kihara, H., et al., "Antithrombotic activity of AT-1015, a potent 5-HT <sub>2A</sub> receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time", <i>European Journal of Pharmacology</i> , vol. 433, pp. 157-162, 2001.
	AAA	Kim, H.J., et al., "Acute effects of serotonin on rat bladder contractility", <i>Urologia Internationalis</i> , vol. 68, pp. 44-48, 2002.
	ABB	Kobori, S., et al., "Effect of 5-hydroxytryptamine <sub>2A</sub> receptor antagonist on the development of diabetic nephropathy in early stage", <i>Diabetes Mellitus: Recent Advances for the 21<sup>st</sup> Century</i> , pp. 283-286, 2000.
	ACC	Kodama, M., et al., "Influence of 5-hydroxytryptamine and the effect of a new serotonin receptor antagonist (sarpogrelate) on detrusor smooth muscle of streptozotocin-induced diabetes mellitus in the rat", <i>International Journal of Urology</i> , vol. 7, pp. 231-235, 2000.
	ADD	Leysen, D., et al., "5-HT <sub>2</sub> antagonists: a concept for the treatment of schizophrenia", <i>Current Pharmaceutical Design</i> , vol. 3, pp. 367-390, 1997.
	AEE	Malyszko, J., et al., "Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes", <i>Thrombosis Research</i> , vol. 75(5), pp. 569-576, 1994.
	AFF	Mano, T., et al., "The effect of anplag (sarpogrelate HCl), new selective 5-HT <sub>2</sub> antagonist on intraocular pressure in rabbits", <i>Investigative Ophthalmology &amp; Visual Science</i> , vol. 36(4), pp. 3322-3309, 1995.
	AGG	Martinez-De Jesus, F.R., et al., "Randomized single-blind trial of topical ketanserin for healing acceleration of diabetic foot ulcers", <i>Archives of Medical Research</i> , vol. 28(1), pp. 95-99, 1997.
	AHH	Menendez, V., et al., "Urodynamic evaluation in simultaneous insulin-dependent diabetes mellitus and end stage renal disease", <i>The Journal of Urology</i> , vol. 155, pp. 2001-2004, 1996.
	AII	Mermoud, A., et al., "Le traitement du glaucome a pression normale avec un antagoniste des recepteurs S2 de la serotonine, le naftidrofuryl (praxilen)", <i>Klin. Mbl. Augenheilk.</i> , vol. 198, pp. 332-334, 1991.
	AJJ	Mermoud, A., et al., "Double-blind study in the treatment of normal tension glaucoma with naftidrofuryl", <i>Ophthalmologica</i> , vol. 201, pp. 145-151, 1990.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13425-122001	Application No. 10/622,055
	Applicant Cernerud et al.		
	Filing Date July 17, 2003	Group Art Unit 1614	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AKK	Nabeshima, T., et al., "Effect of naftidrofuryl oxalate on 5-HT <sub>2</sub> receptors in mouse brain: evaluation based on quantitative autoradiography and head-twitch response", <i>European Journal of Pharmacology</i> , vol. 223, pp. 109-115, 1992.
	ALL	Obata, H., et al., "Antinociception in rat by sarpogrelate, a selective 5-HT <sub>2A</sub> receptor antagonist, is peripheral", <i>European Journal of Pharmacology</i> , vol. 404, pp. 95-102, 2000.
	AMM	Ogawa, S., et al., "The 5-HT <sub>2</sub> receptor antagonist sarpogrelate reduces urinary and plasma levels of thromboxane A <sub>2</sub> and urinary albumin excretion in non-insulin-dependent diabetes mellitus patients", <i>Clinical and Experimental Pharmacology and Physiology</i> , vol. 26, pp. 461-464, 1999.
	ANN	Otake, T., et al., "Bone atrophy in complex regional pain syndrome patients measured by microdensitometry", <i>Canadian Journal of Anesthesiology</i> , vol. 45(9), pp. 831-838, 1998.
	AOO	Pietraszek, M.H., et al., "Blood serotonergic mechanisms in type 2 (non-insulin-dependent) diabetes mellitus", <i>Thrombosis Research</i> , vol. 66, pp. 765-774, 1992.
	APP	Pietraszek, M.H., et al., "Enhanced platelet response to serotonin in diabetes mellitus in relationship to vascular complications", <i>Thromb. Haemost.</i> 1991, 65, 985 (Abstract Only)
	AQQ	Pietraszek, M.H., et al., "The effect of MCI-9042 on serotonin-induced platelet aggregation in type 2 diabetes mellitus", <i>Thrombosis Research</i> , vol. 70, pp. 131-138, 1993.
	ARR	Radulovacki, M., et al., "Ketanserin, a 5-HT <sub>2</sub> receptor antagonist, reduces sleep apneas in rats", <i>Research Communications in Biological Psychology and Psychiatry</i> , vol. 26 (1,2), 2001.
	ASS	Robertson, S.C., et al., "Effects of serotonin (5-HT) and selective 5-HT receptor antagonists on regional cerebral blood flow after middle cerebral artery occlusion", <i>Surgical Forum</i> , pp. 561-563.
	ATT	Saxena, P.R., et al., "Excitatory 5-hydroxytryptamine receptors in the cat urinary bladder are of the M- and 5-HT <sub>2</sub> -type", <i>Journal of Autonomic Pharmacology</i> , vol. 5, pp. 101-107, 1985.
	AUU	Schechter, L.E., et al., "Serotonergic antidepressants: current and future perspectives", <i>CPNS Investigational Drugs</i> , vol. 7(4), pp. 432-447, 1999.
	AVV	Sorbera, L.A., et al., "MDL-100907", <i>Drugs of the Future</i> , vol. 23(9), pp. 955-965, 1998.
	AWW	Stratz, T., et al., "Blockierung der 5-HT <sub>2</sub> -rezeptoren – ein neues behandlungsspringzip der generalisierten tendomyopathie (fibromyalgie)?", <i>Zeitschrift für Rheumatologie</i> , vol. 50, pp. 21-22, 1991. (Abstract Only)
	AXX	Sugimoto, S., et al., "Characteristics of 5-HT <sub>2A</sub> receptors in the bladder smooth muscle of diabetic rats", <i>Nihon. Univ. J. Med.</i> , vol. 43, pp. 141-152, 2001.
	AYY	Sumiyoshi, T., et al., "The effect of streptozotocin-induced diabetes on dopamine <sub>2</sub> , serotonin 1A, and serotonin 2A receptors in the rat brain", <i>Neuropsychopharmacology</i> , vol. 16(3), 183-190, 1997.
	AZZ	Takei, I., et al., "Effects of the 5-HT <sub>2</sub> receptor antagonist sarpogrelate on diabetic vascular disease", <i>Diabetes Research</i> , vol. 34, pp. 239-246, 1999.
	AAAA	Takenaka, H., et al., "The effect of anlag (sarpogrelate HCL), novel selective 5-HT <sub>2</sub> antagonist on intraocular pressure in glaucoma patients", <i>Invest. Ophthalmol. Vis. Sci.</i> 1995, 36, S734. (Abstract Only)
	ABBB	Takimoto, Y., et al., "The effect of 5-HT <sub>2</sub> antagonist for urinary frequency symptom on diabetes mellitus patients", <i>Jpn. J. Urol.</i> vol. 90(8), pp. 731-740, 1999. (Abstract Only)
	ACCC	Tammela, T.L.J., et al., "Temporal changes in micturition and bladder contractility after sucrose diuresis and streptozotocin-induced diabetes mellitus in rats", <i>The Journal of Urology</i> , vol. 153, pp. 2014-2021, 1995.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13425-122001	Application No. 10/622,055
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Cernerud et al.	
		Filing Date July 17, 2003	Group Art Unit 1614

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	ADDD	Tokunaga, A., et al., "5-HT <sub>2A</sub> receptor subtype is involved in the thermal hyperalgesic mechanism of serotonin in the periphery", <i>Pain</i> , vol. 76, pp. 349-355, 1998.
	AEEE	Viola, A.U., et al., "Ritaserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers", <i>Clinical Neurophysiology</i> , vol. 113, pp. 429-434, 2002.
	AFFF	Weinberger, D.R., et al., "Cognitive function in schizophrenia", <i>International Clinical Psychopharmacology</i> , vol. 12(supp.), pp. S29-S36, 1997.
	AGGG	Yoshida, A., et al., "5-hydroxytryptamine receptors, especially the 5-HT <sub>4</sub> receptor, in guinea pig urinary bladder", <i>Jpn. J. Pharmacol.</i> , vol. 89, pp. 349-355, 2002.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	